Cogent Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Feb 17, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 17, 2026

COGT$31.64-5.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Series A Non-Voting Convertible · Series B Non-Voting Convertible · Additional · Accumulated · Total
Preferred Stock · Preferred Stock · Common Stock · Paid-in · Other Comprehensive · Accumulated · Stockholders’
Shares · Amount · Shares · Amount · Shares · Amount · Capital · (Income) Loss · Deficit · Equity
Balances at December 31, 2022	81,050	$65,830	—	$—	69,893,434	$70	$601,153	$(104)	$(411,214)		$255,735
Issuance of common stock in underwritten public offering, net of offering costs of $10.7 million	—	—	—	—	14,375,000	14	161,775	—	—		161,789
Conversion of Series A non-voting convertible preferred stock into common stock	(6,585)	(5,795)	—	—	1,646,250	2	5,793	—	—		—
Issuance of common stock under Employee Stock Purchase Plan	—	—	—	—	85,878	—	752	—	—		752
Issuance of common stock from exercises	—	—	—	—	123,687	—	965	—	—		965
Unrealized gains on marketable securities	—	—	—	—	—	—	—	350	—		350
Stock-based compensation expense	—	—	—	—	—	—	30,621	—	—		30,621
Net loss	—	—	—	—	—	—	—	—	(192,410)		(192,410)
Balances at December 31, 2023	74,465	$60,035	—	$—	86,124,249	$86	$801,059	$246	$(603,624)		$257,802
Issuance of Series B non-voting convertible preferred stock and common stock, net of issuance costs of $11.7 million, in connection with the Private Placement	—	—	12,280	87,311	17,717,997	18	125,958	—	—		213,287
Exchange of common stock for Series B non-voting convertible preferred stock	—	—	8,300	74,754	(8,300,000)	(8)	(74,746)	—	—		—
Conversion of Series B non-voting convertible preferred stock into common stock	—	—	(13,712)	(107,980)	13,712,000	13	107,967	—	—		—
Conversion of Series A non-voting convertible preferred stock into common stock	(4,000)	(3,520)	—	—	1,000,000	1	3,519	—	—		—
Issuance of common stock under Employee Stock Purchase Plan	—	—	—	—	176,893	—	916	—	—		916
Issuance of common stock from exercises	—	—	—	—	30,590	—	199	—	—		199
Unrealized gains on marketable securities	—	—	—	—	—	—	—	201	—		201
Stock-based compensation expense	—	—	—	—	—	—	39,740	—	—		39,740
Net loss	—	—	—	—	—	—	—	—	(255,859)		(255,859)
Balances at December 31, 2024	70,465	$56,515	6,868	$54,085	110,461,729	$110	$1,004,612	$447	$(859,483)		$256,286
Issuance of common stock in underwritten public offerings, net of offering costs of $35.3 million	—	—	—	—	36,684,589	37	539,675	—	—		539,712
Issuance of common stock under ATM, net of issuance costs of $4.9 million	—	—	—	—	7,623,189	8	159,315	—	—		159,323
Conversion of Series A non-voting preferred stock into common stock	(3,051)	(2,685)	—	—	762,750	1	2,684	—	—		—
Conversion of Series B non-voting preferred stock into common stock	—	—	(2,352)	(18,522)	2,352,000	2	18,520	—	—		—
Restricted stock units vesting	—	—	—	—	2,794,000	—	—			—
Shares withheld related to net share settlement of equity awards	—	—	—	—	(1,239,443)	—	(48,896)			(48,896)
Issuance of common stock from exercises	—	—	—	—	1,327,446	2	11,544	—	—		11,546
Issuance of common stock under Employee Stock Purchase Plan	—	—	—	—	213,764	1	1,349	—	—		1,350
Stock-based compensation expense	—	—	—	—	—	—	46,079	—	—		46,079
Unrealized losses on marketable securities	—	—	—	—	—	—	—	(92)	—		(92)
Net loss	—	—	—	—	—	—	—	—	(328,937)		(328,937)
Balances at December 31, 2025	67,414	$53,830	4,516	$35,563	160,980,024	$161	$1,734,882	$355	$(1,188,420)		$636,371

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.